News

Earlier End-of-Life Talks Deter Aggressive Care of Terminal Cancer Patients

View on the News

Timing of Discussions Important

This is an important study that documents the fact that early discussions about end-of-life care for patients with stage IV cancer are associated with decreased intensity of care at the end of life, and that the timing of the initiation of these discussions is very important and should happen earlier than it does much of the time.

This is not the first study to show that this communication is associated with decreased intensity of care (JAMA 2008;300:1665-73). However, this is an important study because it is the first to document that early discussions are important (prior to the last 30 days of life).


Dr. J. Randall Curtis

Moving end-of-life discussions closer to diagnosis definitely is realistic and the way this should occur. However, it is not an "either-or" situation. Early discussions don’t mean that later discussions aren’t necessary and important. Early discussions set the frame and make it easier to have later discussions if/when patients get worse.

There is a need for physicians to improve communication to make sure patients or their surrogates understand end-of-life discussions. Our challenge now is to find successful ways to teach these communication skills to physicians and help physicians implement these discussions in clinical practice. It is not useful to tell physicians to have these discussions if they haven’t been trained to do it well, and we don’t create systems that make it practical and feasible.

When the Obama administration tried to implement a policy of paying physicians to conduct advance care planning on an annual basis through Medicare, Sarah Palin and others used the "death panel" scare tactics to defeat this important effort. We need to change the public discussion to be more aware of the importance of early and regular discussions about advance care planning.

We also need research to figure out how best to implement "earlier discussions" in clinical practice and to identify the long-term consequences of such a practice.

Dr. J. Randall Curtis is director of the University of Washington Palliative Care Center of Excellence and head of Pulmonary and Critical Care Medicine at Harborview Medical Center, Seattle. He provided these comments in an interview. Dr. Curtis reported having no financial disclosures.


 

FROM THE JOURNAL OF CLINICAL ONCOLOGY

"It’s something that any physician can do," but some previous studies report that physicians are reluctant to start end-of-life discussions early because these are emotionally difficult conversations, they worry about taking away hope, and they are concerned about the psychological impact on patients – though there is no clear evidence that it does have psychological consequences for patients, Dr. Mack said.

"It’s a compassionate instinct," she said. "Being in the room with a family when I deliver this kind of news, that emotional impact is right in front of me. I believe there are bigger consequences" from not discussing end-of-life care, such as perpetuating false hopes and asking people to make decisions about what’s ahead without a clear picture of the situation, she added.

The conversation should take place more than once because patient preferences may change over time and patients need time to process the information and their thoughts about it, Dr. Mack said.

Ask Patients What They Hear

Further work is needed on why some documented end-of-life discussions were not reported by patients/surrogates. "Every physician can relate to this, that sometimes we have conversations but they’re not heard or understood by patients," she said. "It reminds me that I need to ask patients what they’re taking away from these conversations and use that to guide me going forward."

That finding echoes two recent large, population-based studies that found many patients with terminal cancer mistakenly think that palliative chemotherapy or radiation will cure their disease.

Some previous studies suggest that patients dying of cancer increasingly are receiving aggressive care at the end of life and that this trend may be modifiable. Cross-sectional studies that assessed one point in time between diagnosis and death have shown that many patients don’t have end-of-life discussions, but these studies probably missed discussions closer to death, Dr. Mack noted.

Other studies have reported an association between having end-of-life discussions and reduced intensity in care. The current study was longitudinal and is one of the first to look at the effects of the timing of these discussions and other factors.

Most patients who realize that they are dying do not want aggressive care, previous studies have shown. Other studies report that less-aggressive end-of-life care is easier on family members and less expensive.

Guidelines from the National Comprehensive Cancer Network, the National Consensus Project for Quality Palliative Care, the American Society of Clinical Oncology, and the American College of Physicians and American Society of Internal Medicine recommend beginning end-of-life discussions early for patients with incurable cancer.

When investigators conducted secondary analyses that excluded patients from Veterans Affairs sites or excluded interviews with patient surrogates, the findings were similar to results of the main analysis.

In the current analysis, 82% of patients had lung cancer, and the rest had colorectal cancer.

Future research on this topic could take many paths, Dr. Mack suggested, including implementing routine early discussions and seeing whether that alters the intensity of final care. Much more could be learned about the quality of discussions between physicians and patients. The current study had no data on discussions led by nurses or social workers or that took place among family members without a medical provider present.

"We’re also interested in looking at a longer trajectory of end-of-life decision making" for patients with incurable cancer – from diagnosis to death, she said.

Dr. Mack and her associates reported having no financial disclosures.

Pages

Recommended Reading

Management of Zollinger-Ellison May Depend on Presence of Tumors
MDedge Hematology and Oncology
Immunomodulator MGN1703 Cuts Risk of Colorectal Cancer Progressing
MDedge Hematology and Oncology
Evidence Mounts for Continuing Bevacizumab After Colorectal Cancer Progresses
MDedge Hematology and Oncology
Lower Treatment Cost Doesn't Mean Lower Quality Care
MDedge Hematology and Oncology
Concurrent Sorafenib and SBRT Too Toxic in Liver Cancer
MDedge Hematology and Oncology
Fatty Liver Disease Cited for Rise in Hepatocellular Carcinoma
MDedge Hematology and Oncology
Sanofi Discounts Cancer Drug by 50% After Backlash
MDedge Hematology and Oncology
Oncologist Roundtable: Is the Zaltrap Reversal a 'Watershed Moment' in Drug Pricing?
MDedge Hematology and Oncology
Antivirals Linked to Lower Risk of Liver Cancer Return
MDedge Hematology and Oncology
Community Oncology Podcast - Cetuximab and FOLFIRI in colon cancer
MDedge Hematology and Oncology